As Exact Sciences (EXAS) Market Value Rose, Holder Cam Group Holding A Has Decreased Its Stake by $450,260; Hanson & Doremus Investment Management Upped Its Stericycle (SRCL) Holding by $604,423; Valuation Declined

January 20, 2018 - By Louis Casey

Hanson & Doremus Investment Management increased its stake in Stericycle Inc (SRCL) by 72.66% based on its latest 2017Q3 regulatory filing with the SEC. Hanson & Doremus Investment Management bought 8,513 shares as the company’s stock declined 1.87% while stock markets rallied. The institutional investor held 20,230 shares of the basic industries company at the end of 2017Q3, valued at $1.45 million, up from 11,717 at the end of the previous reported quarter. Hanson & Doremus Investment Management who had been investing in Stericycle Inc for a number of months, seems to be bullish on the $6.15 billion market cap company. The stock increased 0.66% or $0.47 during the last trading session, reaching $72. About 806,360 shares traded. Stericycle, Inc. (NASDAQ:SRCL) has declined 14.12% since January 20, 2017 and is downtrending. It has underperformed by 30.82% the S&P500.

Cam Group Holding A decreased its stake in Exact Sciences Corp (EXAS) by 5.89% based on its latest 2017Q3 regulatory filing with the SEC. Cam Group Holding A sold 9,580 shares as the company’s stock rose 53.09% with the market. The institutional investor held 153,130 shares of the commercial physical & biological resarch company at the end of 2017Q3, valued at $7.22M, down from 162,710 at the end of the previous reported quarter. Cam Group Holding A who had been investing in Exact Sciences Corp for a number of months, seems to be less bullish one the $5.73B market cap company. The stock decreased 1.99% or $0.97 during the last trading session, reaching $47.82. About 4.78M shares traded or 112.97% up from the average. Exact Sciences Corporation (NASDAQ:EXAS) has risen 458.24% since January 20, 2017 and is uptrending. It has outperformed by 441.54% the S&P500.

Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.05, from 0.94 in 2017Q2. It dropped, as 42 investors sold SRCL shares while 185 reduced holdings. 54 funds opened positions while 148 raised stakes. 78.02 million shares or 2.16% more from 76.38 million shares in 2017Q2 were reported. 100 are owned by Plante Moran Financial Advisors Limited Liability. Spears Abacus Advsr Limited Liability Corp holds 9,331 shares. Albion Finance Group Ut reported 0.06% in Stericycle, Inc. (NASDAQ:SRCL). Ameriprise Fincl has 0.03% invested in Stericycle, Inc. (NASDAQ:SRCL). Proshare Advsr Ltd Co holds 19,978 shares. Benjamin F Edwards And Inc has 3,840 shares for 0.03% of their portfolio. Godshalk Welsh Capital stated it has 0.58% of its portfolio in Stericycle, Inc. (NASDAQ:SRCL). Liberty Mutual Grp Inc Asset Inc reported 0.01% in Stericycle, Inc. (NASDAQ:SRCL). Prentiss Smith And Inc invested 0.15% of its portfolio in Stericycle, Inc. (NASDAQ:SRCL). Clearbridge Lc owns 0.06% invested in Stericycle, Inc. (NASDAQ:SRCL) for 928,931 shares. Payden Rygel accumulated 1,200 shares or 0.01% of the stock. Washington owns 7,486 shares. S&Co owns 49,695 shares. Moreover, Us Commercial Bank De has 0.02% invested in Stericycle, Inc. (NASDAQ:SRCL). Axa owns 124,875 shares.

Since October 30, 2017, it had 0 insider buys, and 1 insider sale for $1.39 million activity.

Among 15 analysts covering Stericycle (NASDAQ:SRCL), 5 have Buy rating, 3 Sell and 7 Hold. Therefore 33% are positive. Stericycle had 51 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Robert W. Baird given on Friday, May 5. RBC Capital Markets maintained the shares of SRCL in report on Friday, August 4 with “Sell” rating. As per Wednesday, October 11, the company rating was maintained by RBC Capital Markets. The firm has “Outperform” rating given on Wednesday, October 5 by Barrington Research. The firm earned “Buy” rating on Friday, November 10 by Jefferies. Jefferies maintained it with “Buy” rating and $108.0 target in Friday, September 15 report. The rating was maintained by Robert W. Baird on Tuesday, October 10 with “Sell”. The rating was maintained by Barrington Research with “Outperform” on Wednesday, February 22. Imperial Capital maintained the stock with “In-Line” rating in Monday, October 26 report. The firm earned “Outperform” rating on Friday, October 23 by Macquarie Research.

Cam Group Holding A, which manages about $7.04 billion US Long portfolio, upped its stake in Gilead Sciences Inc (NASDAQ:GILD) by 58,216 shares to 4.31 million shares, valued at $348.96 million in 2017Q3, according to the filing. It also increased its holding in Amazon Inc (NASDAQ:AMZN) by 6,680 shares in the quarter, for a total of 302,601 shares, and has risen its stake in Glaukos Corp.

Investors sentiment decreased to 1.01 in Q3 2017. Its down 0.26, from 1.27 in 2017Q2. It dived, as 39 investors sold EXAS shares while 81 reduced holdings. 44 funds opened positions while 77 raised stakes. 93.65 million shares or 1.18% less from 94.77 million shares in 2017Q2 were reported. Jane Street Gp Limited Liability Corp reported 7,285 shares. Proshare Advisors Limited Liability reported 10,923 shares. Perigon Wealth Mgmt Limited Co accumulated 30 shares. New York-based Jennison Assocs Limited Liability has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Kistler reported 315 shares stake. Gotham Asset Mgmt Ltd Liability Company, New York-based fund reported 336,919 shares. Sit Invest Associates reported 29,900 shares stake. Gofen Glossberg Limited Liability Company Il accumulated 0.02% or 9,200 shares. 4.08M were reported by D E Shaw & Communications. C Ww Gp Holding A S holds 0.1% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 153,130 shares. Millennium Management Lc holds 0% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 38,425 shares. Sg Americas Ltd Liability Com owns 0% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 3,886 shares. Credit Suisse Ag holds 0.01% or 216,217 shares in its portfolio. Chicago Equity Partners Ltd Llc has invested 0.07% in Exact Sciences Corporation (NASDAQ:EXAS). Price T Rowe Associate Inc Md has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS).

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 10 have Buy rating, 1 Sell and 7 Hold. Therefore 56% are positive. EXACT Sciences had 62 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Benchmark on Wednesday, May 31. The rating was maintained by Roth Capital on Wednesday, July 26 with “Buy”. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Monday, November 13 by Leerink Swann. The firm has “Buy” rating given on Wednesday, October 7 by Mizuho. On Thursday, October 19 the stock rating was maintained by Bank of America with “Buy”. The firm has “Neutral” rating by Wedbush given on Thursday, October 8. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Canaccord Genuity on Tuesday, October 3. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Outperform” rating by Leerink Swann on Tuesday, October 31. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Neutral” rating by Roth Capital on Thursday, February 25. The firm has “Buy” rating by BTIG Research given on Friday, December 18.

Since September 1, 2017, it had 0 buys, and 6 insider sales for $16.89 million activity. LIDGARD GRAHAM PETER had sold 75,683 shares worth $3.09M on Tuesday, September 5. Conroy Kevin T sold $6.62 million worth of stock.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on February, 20. They expect $-0.29 earnings per share, up 14.71% or $0.05 from last year’s $-0.34 per share. After $-0.23 actual earnings per share reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 26.09% negative EPS growth.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>